Wendy Stock to Protein-Tyrosine Kinases
This is a "connection" page, showing publications Wendy Stock has written about Protein-Tyrosine Kinases.
Connection Strength
0.966
-
RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Apr; 56(4):1145-7.
Score: 0.427
-
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 Jan; 15(1):26-36.
Score: 0.126
-
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841.
Score: 0.124
-
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2010 Feb; 51(2):188-98.
Score: 0.078
-
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006 Jul 01; 108(1):28-37.
Score: 0.059
-
Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads. Anal Biochem. 2005 Dec 01; 347(1):67-76.
Score: 0.057
-
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Mol Cell. 2021 09 16; 81(18):3833-3847.e11.
Score: 0.043
-
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11; 371(11):1005-15.
Score: 0.027
-
CGG-repeat polymorphism of the BCR gene rules out predisposing alleles leading to the Philadelphia chromosome. Genes Chromosomes Cancer. 1994 Feb; 9(2):141-4.
Score: 0.026